Supplementary material
Supplementary material
Files in this Data Supplement:
- Supplementary material -
SUPPLEMENTARY TABLE 1 Number and percentage of patients from the various countries involved in the studies
SUPPLEMENTARY TABLE 2 Baseline characteristics stratified by use of short-acting muscarinic antagonist (SAMA) and previous treatment with inhaled corticosteroids (ICS)
SUPPLEMENTARY TABLE 3 Mean rate of moderate or severe exacerbations per patient per year in patients who received and did not receive treatment with long-acting β2 agonists (LABAs) before study start. Intention-to-treat analysis
SUPPLEMENTARY TABLE 4 Mean rate of moderate or severe exacerbations per patient per year by concomitant treatment with a short-acting muscarinic antagonist (SAMA) and treatment with inhaled corticosteroid (ICS) during run-in. Intention-to-treat analysis
SUPPLEMENTARY TABLE 5 Time to onset of first, second, or third moderate or severe exacerbation in all patients, those receiving concomitant treatment with/without short-acting muscarinic antagonist (SAMA), and with/without treatment with inhaled corticosteroid (ICS) during run-in. Intention-to-treat analysis
SUPPLEMENTARY TABLE 6 Mean change (improvement) in transitional dyspnoea index (TDI) focal score by repeated measurements analysis and also by last observation carried forward (LOCF). Intention-to-treat analysis. TDI is graded from 0 to 4, where 0 is most severe; a change in TDI score of 1.0 unit is considered clinically relevant
SUPPLEMENTARY TABLE 7 Mean change in pre- and post-bronchodilator FEV1 (least square means) according to concomitant treatment with a long-acting β2 agonist (LABA), frequency of previous exacerbations, concomitant treatment with a short-acting muscarinic antagonist (SAMA) and previous treatment with inhaled corticosteroid (ICS). Intention-totreat analysis
Interaction testing
SUPPLEMENTARY TABLE 8 Mean change in pre- and post bronchodilator FEV1 by repeated measurements analysis and also by last observation carried forward (LOCF)